BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Sep 13, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Arbaclofen: Phase II data

In the per protocol (PP) population (n=25) of an open-label, U.S. Phase II trial, STX209 met the primary endpoint of significantly improving irritability subscale scores on the ABC-I from baseline to week 8 (p<0.001). STX209 also significantly improved global and specific neurobehavioral outcomes from baseline, including the Social Withdrawal subscale of the ABC (ABC-SW) (p<0.001) and the ABC-Total scale (p<0.001). Additionally, STX209 significantly improved investigators' assessments of Clinical Global Impressions of Improvement (CGI-I) (p=0.001) and Severity (CGI-S) (p=0.002)...

Read the full 368 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >